Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Practical model-based dose-finding in phase I clinical trials: methods based on toxicity.

P F Thall1, S-J Lee

  • 1Department of Biostatistics, University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA. rex@mdanderson.org

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|June 13, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction Note: Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells.

Oncogene·2026
Same author

Colonic phytobezoar.

BMJ case reports·2025
Same author

Three-Dimensional Computed Tomography Image Reformation for Comparison of Foraminal Cross-Sectional Dimension in Patients Who Have Undergone Laminoplasty and Laminectomy with Fusion.

Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca·2024
Same author

Regional and annual patterns in respiratory virus co-infection etiologies and antibiotic prescriptions for pediatric mycoplasma pneumoniae pneumonia.

European review for medical and pharmacological sciences·2022
Same author

The Safety of Intra-arterial Tirofiban during Endovascular Therapy after Intravenous Thrombolysis.

AJNR. American journal of neuroradiology·2021
Same author

Two-Dimensional Superconducting Fluctuations Associated with Charge-Density-Wave Stripes in La_{1.87}Sr_{0.13}Cu_{0.99}Fe_{0.01}O_{4}.

Physical review letters·2021
Same journal

Updated pocket guide for integrated risk stratification in endometrial carcinoma: a practical tool based on European Society of Gynecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology 2025 guidelines.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same journal

How long is enough? Immunotherapy duration in mismatch repair deficient endometrial cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same journal

In-transit lymph node metastases in the ovarian pedicle in early-stage ovarian cancer: myth or reality?

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same journal

The PROMISE-EC Study: prognostic role of molecular classification and sentinel lymph node status in early-stage endometrial cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same journal

Beyond MEK inhibition: exploring MAPK pathway dependency in low-grade serous ovarian carcinoma.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same journal

Platinum sensitivity: is time still enough?

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
See all related articles

Bayesian statistical methods offer a more reliable approach to finding the maximum tolerable dose (MTD) in early-phase clinical trials compared to traditional algorithms. These adaptive methods improve patient safety by minimizing exposure to overly toxic drug doses.

Area of Science:

  • Clinical Trials
  • Biostatistics
  • Pharmacology

Background:

  • Phase I clinical trials aim to determine the maximum tolerable dose (MTD) of new therapies.
  • Traditional dose-finding algorithms, like the 3+3 method, have limitations in efficiency and safety.
  • Outcome-adaptive statistical methods offer potential improvements in dose selection.

Purpose of the Study:

  • To introduce and compare two Bayesian, outcome-adaptive statistical methods for dose-finding in phase I clinical trials.
  • To evaluate the performance of these Bayesian methods against the conventional 3+3 algorithm.
  • To assess the reliability and safety of Bayesian methods in selecting an MTD.

Main Methods:

  • Description of the continual reassessment method (CRM).

Related Experiment Videos

  • Description of a logistic regression model-based method.
  • Utilizing Bayesian probability models for adaptive dose selection based on accruing trial data.
  • Comparison via simulation studies and application to a renal cell carcinoma trial.

    • Main Results:

    • Bayesian methods demonstrated superior reliability in selecting the MTD compared to the 3+3 algorithm.
    • Computer simulations indicated a low risk of patient exposure to unacceptably toxic doses with Bayesian approaches.
    • The methods were illustrated using a real-world clinical trial example.

    Conclusions:

    • Bayesian outcome-adaptive methods are more effective and safer for dose-finding in phase I trials.
    • These advanced statistical techniques enhance the precision of MTD determination.
    • The findings support the adoption of Bayesian methods over conventional algorithms for improved clinical trial design.